Selling AI into healthcare has a problem no other sector has quite so sharply. The buyer is a clinician or an administrator who has been promised transformative technology before, who is accountable if it harms a patient, and who has heard the word “AI” used to describe everything from a decision-support system to a chatbot with a form behind it.
Drive Health builds clinical workflow automation, including an assistant named Avery. This is about designing a product website for a sector where overclaiming is not just bad marketing, it is disqualifying.
Key Takeaways
- In clinical software, stating the limits of the system builds more confidence than describing its capabilities.
- Naming the product, rather than talking about “our AI”, gives buyers something concrete to evaluate and remember.
- Healthcare buyers segment by care setting, not by feature. The site structure should follow how they are organised, not how the product is built.
- A demo request is the real conversion, and the page has to earn it by being specific about what the demo shows.
What Does Drive Health Do?
Drive Health describes a clinical workflow automation engine that handles routine tasks such as patient outreach and message triage, operating under clinician oversight, with the stated aim of reducing administrative burden on care teams. The assistant is named Avery.
The site is organised around care settings rather than features, with sections covering transitional and chronic care, episodic care, preventative care, accountable care organisations, government-direct work and healthcare systems.
Why Does Restraint Matter More Than Ambition Here?
Because the buyer’s default assumption is that the claims are inflated, and the fastest way to confirm that suspicion is to make a big one.
The phrase that does the most work on this site is “under strict clinician oversight”. It is a limitation, and it is the most persuasive thing on the page.
A clinician reading about automated patient outreach immediately asks who is accountable when the automation gets it wrong. A site that answers by describing how capable the system is has not answered. A site that says the clinician remains in the loop has answered the actual question, and in doing so has signalled that the people who built it understand the setting.
The same logic applies to scope. Describing the system as handling routine tasks, and naming them as outreach and message triage, is far stronger than claiming to transform care delivery. Specific and bounded reads as real. Broad and visionary reads as a pitch deck.
Name the product
Calling the assistant Avery, and letting it introduce itself on the page, does something that “our AI platform” cannot. It gives the buyer a noun. In an internal conversation, someone can say “we looked at Avery” rather than “we looked at an AI thing for triage”, and that difference decides whether a product survives the week after the demo.
It also sets expectations honestly. A named assistant with a defined job is easier to evaluate than a platform whose boundaries are unstated.
How Should a Healthcare Product Site Be Structured?
Around the buyer’s organisation, not the product’s architecture.
The instinct of most software companies is to structure the site by capability: automation, analytics, integrations, security. That maps to how the engineering team thinks and to nobody else. A healthcare buyer does not wake up looking for automation. They work in an accountable care organisation with a specific population and a specific set of pressures.
Drive Health’s site splits by care setting instead, so a visitor can find the page that matches their world and read about the problems they actually have. This is harder to write, because it requires understanding each setting well enough to describe its pressures credibly, and it is the difference between a site that gets forwarded internally and one that gets closed.
The government path is separate for a reason
Government and public-sector healthcare buying works differently: different procurement, different compliance, different timelines. Giving it a distinct path rather than folding it into a general enterprise page respects that, and stops the commercial pages from being cluttered with procurement language most visitors do not need.
What Carries the Proof?
Three things, and their order matters.
Named partners come first, because in healthcare an institution’s willingness to be named is itself the endorsement. Named experts come next: a clinical product’s credibility rests substantially on who built it and whether clinicians were involved rather than consulted. Published thinking comes third, and the site carries articles including work on how nurses relate to agentic AI in caregiving, which is the kind of content that signals engagement with the profession rather than at it.
What is deliberately not the proof is outcome statistics without provenance. A percentage reduction in administrative time, quoted without the study, the sample or the setting, is read by this audience as marketing. The same number with its source attached is evidence. We would rather publish fewer numbers with citations than more without.
What Is the Conversion, and What Does It Need?
A demo, and the demo request has to be earned by specificity.
Healthcare buyers are cautious about demos because they cost an hour and often deliver a generic slideshow. A demo page that says what will actually be shown, and for which care setting, converts better than a form headed “Get in touch”. The site also carries a “seeing is believing” framing, which is the right instinct: for a product whose value is operational, watching it work beats reading about it.
What We Would Watch
Regulatory language ages and varies by jurisdiction. Any claim touching clinical safety, data protection or approval status needs a named owner and a review cycle, and it should be drafted with the client’s compliance function rather than by an agency. We will build the section and say what it needs to cover. We are not the right people to decide what may be claimed.
The second is the gap between the named assistant and the underlying platform. Products like this tend to grow beyond their original scope, and a site built tightly around one named assistant needs a plan for what happens when there are three.
Frequently Asked Questions
How do you market AI without overclaiming?
Describe the specific tasks the system performs, name what stays with a human, and avoid transformation language. In regulated settings, stated limits increase trust rather than reducing it.
Should a software site be organised by feature or by audience?
By audience, in almost every case where the buyer’s world is structured, as healthcare is. Feature-led navigation suits the people who built the product and few of the people considering it.
What proof do healthcare buyers actually want?
Named institutions willing to be associated with the product, clinicians involved in building it, and evidence with its source attached. Unattributed statistics are usually discounted entirely.
Why name an AI assistant?
Because it gives buyers a concrete thing to discuss internally and sets a clearer boundary around what the product does. An unnamed platform is harder to recommend and harder to evaluate.
Selling Into a Cautious Sector?
If your product is genuinely good and your site is not converting, the cause in regulated sectors is often that the claims are too large rather than too small.
See more of our builds in our portfolio, read how we scope work on our process page, or get in touch.
